<?xml version='1.0' encoding='utf-8'?>
<document id="23064958"><sentence text="Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential."><entity charOffset="21-31" id="DDI-PubMed.23064958.s1.e0" text="vismodegib" /><entity charOffset="37-50" id="DDI-PubMed.23064958.s1.e1" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.23064958.s1.e0" e2="DDI-PubMed.23064958.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23064958.s1.e0" e2="DDI-PubMed.23064958.s1.e1" /></sentence><sentence text="Vismodegib, a first-in-class oral hedgehog pathway inhibitor, is an effective treatment for advanced basal cell carcinoma"><entity charOffset="0-10" id="DDI-PubMed.23064958.s2.e0" text="Vismodegib" /></sentence><sentence text=" Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI study with oral contraceptives (OCs)" /><sentence text="" /><sentence text="This single-arm, open-label study included two cohorts of patients with locally advanced or metastatic solid malignancies [Cohort 1: rosiglitazone 4 mg (selective CYP2C8 probe); Cohort 2: OC (norethindrone 1 mg/ethinyl estradiol 35 μg; CYP3A4 substrate)]"><entity charOffset="133-146" id="DDI-PubMed.23064958.s5.e0" text="rosiglitazone" /><entity charOffset="188-190" id="DDI-PubMed.23064958.s5.e1" text="OC" /><entity charOffset="192-205" id="DDI-PubMed.23064958.s5.e2" text="norethindrone" /><entity charOffset="211-228" id="DDI-PubMed.23064958.s5.e3" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e0" e2="DDI-PubMed.23064958.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e0" e2="DDI-PubMed.23064958.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e0" e2="DDI-PubMed.23064958.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e0" e2="DDI-PubMed.23064958.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e1" e2="DDI-PubMed.23064958.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e1" e2="DDI-PubMed.23064958.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e1" e2="DDI-PubMed.23064958.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e2" e2="DDI-PubMed.23064958.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s5.e2" e2="DDI-PubMed.23064958.s5.e3" /></sentence><sentence text=" On Day 1, patients received rosiglitazone or OC"><entity charOffset="29-42" id="DDI-PubMed.23064958.s6.e0" text="rosiglitazone" /><entity charOffset="46-48" id="DDI-PubMed.23064958.s6.e1" text="OC" /><pair ddi="false" e1="DDI-PubMed.23064958.s6.e0" e2="DDI-PubMed.23064958.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23064958.s6.e0" e2="DDI-PubMed.23064958.s6.e1" /></sentence><sentence text=" On Days 2-7, patients received vismodegib 150 mg/day"><entity charOffset="32-42" id="DDI-PubMed.23064958.s7.e0" text="vismodegib" /></sentence><sentence text=" On Day 8, patients received vismodegib plus rosiglitazone or OC"><entity charOffset="45-58" id="DDI-PubMed.23064958.s8.e0" text="rosiglitazone" /><entity charOffset="62-64" id="DDI-PubMed.23064958.s8.e1" text="OC" /><pair ddi="false" e1="DDI-PubMed.23064958.s8.e0" e2="DDI-PubMed.23064958.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23064958.s8.e0" e2="DDI-PubMed.23064958.s8.e1" /></sentence><sentence text=" The effect of vismodegib on rosiglitazone and OC pharmacokinetic parameters (primary objective) was evaluated through pharmacokinetic sampling over a 24-h period (Days 1 and 8)"><entity charOffset="15-25" id="DDI-PubMed.23064958.s9.e0" text="vismodegib" /><entity charOffset="29-42" id="DDI-PubMed.23064958.s9.e1" text="rosiglitazone" /><entity charOffset="47-49" id="DDI-PubMed.23064958.s9.e2" text="OC" /><pair ddi="false" e1="DDI-PubMed.23064958.s9.e0" e2="DDI-PubMed.23064958.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23064958.s9.e0" e2="DDI-PubMed.23064958.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s9.e0" e2="DDI-PubMed.23064958.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s9.e1" e2="DDI-PubMed.23064958.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s9.e1" e2="DDI-PubMed.23064958.s9.e2" /></sentence><sentence text="" /><sentence text="The mean ± SD vismodegib steady-state plasma concentration (Day 8, N = 51) was 20"><entity charOffset="67-68" id="DDI-PubMed.23064958.s11.e0" text="N" /></sentence><sentence text="6 ± 9" /><sentence text="72 μM (range 7" /><sentence text="93-62" /><sentence text="4 μM)" /><sentence text=" Rosiglitazone AUC(0-inf) and C(max) were similar with concomitant vismodegib [≤8% change in geometric mean ratios (GMRs); N = 24]"><entity charOffset="1-14" id="DDI-PubMed.23064958.s16.e0" text="Rosiglitazone" /><entity charOffset="123-135" id="DDI-PubMed.23064958.s16.e1" text="N" /><pair ddi="false" e1="DDI-PubMed.23064958.s16.e0" e2="DDI-PubMed.23064958.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23064958.s16.e0" e2="DDI-PubMed.23064958.s16.e1" /></sentence><sentence text=" Concomitant vismodegib with OC did not affect ethinyl estradiol AUC(0-inf) and C(max) (≤5% change in GMRs; N = 27); norethindrone C(max) and AUC(0-inf) GMRs were higher (12 and 23%, respectively) with concomitant vismodegib"><entity charOffset="13-23" id="DDI-PubMed.23064958.s17.e0" text="vismodegib" /><entity charOffset="47-64" id="DDI-PubMed.23064958.s17.e1" text="ethinyl estradiol" /><entity charOffset="108-109" id="DDI-PubMed.23064958.s17.e2" text="N" /><entity charOffset="117-130" id="DDI-PubMed.23064958.s17.e3" text="norethindrone" /><entity charOffset="29-41" id="DDI-PubMed.23064958.s17.e4" text="OC" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e0" e2="DDI-PubMed.23064958.s17.e0" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e0" e2="DDI-PubMed.23064958.s17.e4" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e0" e2="DDI-PubMed.23064958.s17.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e0" e2="DDI-PubMed.23064958.s17.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e0" e2="DDI-PubMed.23064958.s17.e3" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e4" e2="DDI-PubMed.23064958.s17.e4" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e4" e2="DDI-PubMed.23064958.s17.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e4" e2="DDI-PubMed.23064958.s17.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e4" e2="DDI-PubMed.23064958.s17.e3" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e1" e2="DDI-PubMed.23064958.s17.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e1" e2="DDI-PubMed.23064958.s17.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e1" e2="DDI-PubMed.23064958.s17.e3" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e2" e2="DDI-PubMed.23064958.s17.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s17.e2" e2="DDI-PubMed.23064958.s17.e3" /></sentence><sentence text="" /><sentence text="This DDI study in patients with cancer demonstrated that systemic exposure of rosiglitazone (a CYP2C8 substrate) or OC (ethinyl estradiol/norethindrone) is not altered with concomitant vismodegib"><entity charOffset="78-91" id="DDI-PubMed.23064958.s19.e0" text="rosiglitazone" /><entity charOffset="116-118" id="DDI-PubMed.23064958.s19.e1" text="OC" /><entity charOffset="120-137" id="DDI-PubMed.23064958.s19.e2" text="ethinyl estradiol" /><entity charOffset="138-151" id="DDI-PubMed.23064958.s19.e3" text="norethindrone" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e0" e2="DDI-PubMed.23064958.s19.e0" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e0" e2="DDI-PubMed.23064958.s19.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e0" e2="DDI-PubMed.23064958.s19.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e0" e2="DDI-PubMed.23064958.s19.e3" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e1" e2="DDI-PubMed.23064958.s19.e1" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e1" e2="DDI-PubMed.23064958.s19.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e1" e2="DDI-PubMed.23064958.s19.e3" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e2" e2="DDI-PubMed.23064958.s19.e2" /><pair ddi="false" e1="DDI-PubMed.23064958.s19.e2" e2="DDI-PubMed.23064958.s19.e3" /></sentence><sentence text=" Overall, there appears to be a low potential for DDIs when vismodegib is co-administered with other medications"><entity charOffset="60-70" id="DDI-PubMed.23064958.s20.e0" text="vismodegib" /></sentence><sentence text="" /></document>